Leveraging deep expertise in bispecific antibody engineering, in collaboration with 9Bio Therapeutics, we combine advanced computational modeling with structure-guided design to rapidly develop optimized therapeutic antibody candidates.

We offer multiple antibody engineering and optimization pipelines tailored to the specific needs of each therapeutic program, ranging from rapid sequence-based screening approaches to advanced structure-guided and molecular dynamics-driven computational workflows.

Bispecific and Multispecific Pipelines


	Express	Structure-Guided	High-Resolution Molecular Dynamics
Initial design	✓	✓	✓
Static structural modeling and liability mapping		✓	✓
Dynamic structural modeling confirming steric alignment supporting candidate triage			✓
Sequence liability assessment (deamidation, oxidation, etc.)	✓	✓	✓
Production efficiency evaluation	✓	✓	✓
Affinity measurment (crude extracts)	✓	✓	✓
Purification and manufacturability evaluation	Optional	Optional	Optional
Affinity measurment (purified)	Optional	Optional	Optional
Full report	✓	✓	✓

Format Overview

Knob-Into-Hole and CrossMAb®

Our team has extensive experience developing bispecific antibodies, including successful implementation of heterodimeric IgG engineering workflows from molecular design through expression and characterization. This platform enables efficient assembly, scalable production, and rapid evaluation of next-generation bispecific therapeutics.

IgG-scFv and Antibody Fusion Protein

We have developed an integrated IgG-scFv engineering platform enabling the generation of multifunctional antibody formats with enhanced targeting flexibility and modular design. Our experience includes construct optimization, linker engineering, expression, and functional characterization of IgG-scFv molecules across diverse therapeutic applications.

By combining conventional antibody architectures with engineered single-chain binding domains, we support the development of highly versatile multispecific formats with strong developability and translational potential.

Fusion protein engineering requires careful balancing of stability, expression, folding, and biological activity. Common challenges can include steric hindrance, domain misfolding, aggregation, proteolytic sensitivity, linker-dependent loss of activity, and altered pharmacokinetics. Our workflow incorporates early-stage risk assessment and iterative optimization strategies to identify well-behaved constructs with favorable manufacturability and functional performance

Other Bispecific, Multispecific and Custom Format

Our team can help with the design, production, validation and optimization of a wide range of formats. Design considerations include:

• Optimal format for each paratope

• Position of each arm

• Linker size and composition

• Optimization of affinity and developability

Bispecific and Multispecific Antibodies

Bispecific and trispecific antibodies are gaining traction as revolutionary biologics to treat complex diseases.